Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides

Current Pharmaceutical Design

Volumn 15, Issue 30, 2009, Pages 3577-3589

  Leali, D ^a   Alessi, P ^a   Coltrini, D ^a   Rusnati, M ^a   Zetta, L ^b   Presta, M ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CNR   (Italy)

Author keywords

Angiogenesis; FGF2; Innate immunity; Modeling; NMR; Pentraxin; Synthetic peptides; Tumor

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; PENTRAXIN 3; PROTEOHEPARAN SULFATE; TYROSINE KINASE RECEPTOR;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BINDING AFFINITY; CELL PROLIFERATION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; C-REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 2; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; PEPTIDES;

EID: 70449389165     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789206962     Document Type: Review

References (146)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364 (Pubitemid 26272076)
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
4. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563-569 (Pubitemid 39314564)
5. Fantl WJ, Escobedo JA, Martin GA, Turck CW, Del Rosario M, McCormick F, et al. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 1992; 69: 413-423
6. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002; 8: 483-489
7. Dell'Era P, Belleri M, Stabile H, Massardi ML, Ribatti D, Presta M. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene 2001; 20: 2655-2663 (Pubitemid 32525296)
8. Redington AE, Roche WR, Madden J, Frew AJ, Djukanovic R, Holgate ST, et al. Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge. J Allergy Clin Immunol 2001; 107: 384-387 (Pubitemid 32173920)
9. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 96: 822-828 (Pubitemid 32240738)
10. Yamashita A, Yonemitsu Y, Okano S, Nakagawa K, Nakashima Y, Irisa T, et al. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002; 168: 450-457 (Pubitemid 34014148)
11. Gibran NS, Isik FF, Heimbach DM, Gordon D. Basic fibroblast growth factor in the early human burn wound. J Surg Res 1994; 56: 226-234 (Pubitemid 24100432)
12. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178 (Pubitemid 40616114)
13. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271: 15292-15297 (Pubitemid 26195013)
14. Nicoli S, De Sena G, Presta M. Fibroblast Growth Factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. J Cell Mol Med 2008; [Epub ahead of print].
15. Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Molinari-Tosatti MP, et al. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996; 7: 147-160
16. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-465
17. Schmid MC, Varner JA. Myeloid cell trafficking and tumor angiogenesis. Cancer Lett 2007; 250: 1-8.
18. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995; 92: 4606-4610
19. Baird A, Mormede P, Bohlen P. Immunoreactive fibroblast growth factor in cells of peritoneal exudate suggests its identity with macrophage-derived growth factor. Biochem Biophys Res Commun 1985; 126: 358-364 (Pubitemid 15173569)
20. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 1994; 91: 2890-2894 (Pubitemid 24984860)
21. Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, Eberlein TJ. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA 1995; 92: 6547-6551
22. Ribatti D, Crivellato E, Candussio L, Vacca A, Nico B, Benagiano V, et al. Angiogenic activity of rat mast cells in the chick embryo chorioallantoic membrane is down-regulated by treatment with recombinant human alpha-2a interferon and partly mediated by fibroblast growth factor-2. Haematologica 2002; 87: 465-471 (Pubitemid 34533270)
23. Gloe T, Sohn HY, Meininger GA, Pohl U. Shear stress-induced release of basic fibroblast growth factor from endothelial cells is mediated by matrix interaction via integrin alpha(v)beta3. J Biol Chem 2002; 277: 23453-23458 (Pubitemid 34952179)
24. Hartnett ME, Garcia CM, D'Amore PA. Release of bFGF, an endothelial cell survival factor, by osmotic shock. Invest Ophthalmol Vis Sci 1999; 40: 2945-2951
25. Cozzolino F, Torcia M, Lucibello M, Morbidelli L, Ziche M, Platt J, et al. Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest 1993; 91: 2504-2512 (Pubitemid 23182502)
26. Lee HT, Lee JG, Na M, Kay EP. FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells. J Biol Chem 2004; 279: 32325-32332 (Pubitemid 39014684)
27. Walford G, Loscalzo J. Nitric oxide in vascular biology. J Thromb Haemost 2003; 1: 2112-2118
28. Ziche M, Parenti A, Ledda F, Dell'Era P, Granger HJ, Maggi CA, et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 1997; 80: 845-852 (Pubitemid 27230059)
29. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 2008; 283: 2139-2146
30. Gajdusek CM, Carbon S. Injury-induced release of basic fibroblast growth factor from bovine aortic endothelium. J Cell Physiol 1989; 139: 570-579 (Pubitemid 19167830)
31. Sahni A, Altland OD, Francis CW. FGF-2 but not FGF-1 binds fibrin and supports prolonged endothelial cell growth. J Thromb Haemost 2003; 1: 1304-1310
32. Sahni A, Francis CW. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires {alpha}v{beta}3. Blood 2004; 104: 3635-3641
33. Wang L, Xiong M, Che D, Liu S, Hao C, Zheng X. The effect of hypoxia on expression of basic fibroblast growth factor in pulmonary vascular pericytes. J Tongji Med Univ 2000; 20: 265-7.
34. Li J, Shworak NW, Simons M. Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. J Cell Sci 2002; 115: 1951-1959
35. Tiefenbacher CP, Chilian WM. Basic fibroblast growth factor and heparin influence coronary arteriolar tone by causing endothelium-dependent dilation. Cardiovasc Res 1997; 34: 411-417
36. Reuss B, Dono R, Unsicker K. Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood-brain barrier permeability: evidence from mouse mutants. J Neurosci 2003; 23: 6404-6412 (Pubitemid 36909865)
37. Zhang H, Issekutz AC. Growth factor regulation of neutrophil-endothelial cell interactions. J Leukoc Biol 2001; 70: 225-232 (Pubitemid 32751513)
38. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-3343 (Pubitemid 26115364)
39. Wempe F, Lindner V, Augustin HG. Basic fibroblast growth factor (bFGF) regulates the expression of the CC chemokine monocyte chemoattractant protein-1 (MCP-1) in autocrine-activated endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 2471-2478 (Pubitemid 28015983)
40. Jih YJ, Lien WH, Tsai WC, Yang GW, Li C, Wu LW. Distinct regulation of genes by bFGF and VEGF-A in endothelial cells. Angiogenesis 2001; 4: 313-321 (Pubitemid 34832376)
41. Leali D, Dell'Era P, Stabile H, Sennino B, Chambers AF, Naldini A, et al. Osteopontin (Eta-1) and fibroblast growth factor-2 crosstalk in angiogenesis. J Immunol 2003; 171: 1085-1093 (Pubitemid 36871426)
42. Naldini A, Leali D, Pucci A, Morena E, Carraro F, Nico B, et al. Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol 2006; 177: 4267-4270 (Pubitemid 44469753)
43. Andres G, Leali D, Mitola S, Coltrini D, Camozzi M, Corsini M, et al. A Pro-inflammatory signature mediates FGF2-induced angiogenesis. J Cell Mol Med 2008; [Epub ahead of print].
44. Brower V. Antiangiogenesis research is booming, as questions and studies proliferate. J Natl Cancer Inst 2009; 101: 780-781
45. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
46. Brower V. How well do angiogenesis inhibitors work? biomarkers of response prove elusive. J Natl Cancer Inst 2009; 101: 846-847
47. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 2007; 13: 2025-2044 (Pubitemid 47040487)
48. van Berkel V, Barrett J, Tiffany HL, Fremont DH, Murphy PM, McFadden G, et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 2000; 74: 6741-6747 (Pubitemid 30470656)
49. Parry CM, Simas JP, Smith VP, Stewart CA, Minson AC, Efstathiou S, et al. A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J Exp Med 2000; 191: 573-578 (Pubitemid 30693582)
50. Fallon PG, Alcami A. Pathogen-derived immunomodulatory molecules: future immunotherapeutics? Trends Immunol 2006; 27: 470-476
51. Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, Presta M, Giavazzi R. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 1997; 8: 471-479 (Pubitemid 27273084)
52. Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, et al. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 2003; 102: 4399-4406 (Pubitemid 37494101)
53. Bossard C, Van den Berghe L, Laurell H, Castano C, Cerutti M, Prats AC, et al. Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide. Cancer Res 2004; 64: 7507-7512 (Pubitemid 39372095)
54. Asplin IR, Wu SM, Mathew S, Bhattacharjee G, Pizzo SV. Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)- macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis. Blood 2001; 97: 3450-3457
55. Dennis PA, Saksela O, Harpel P, Rifkin DB. Alpha 2- macroglobulin is a binding protein for basic fibroblast growth factor. J Biol Chem 1989; 264: 7210-7216 (Pubitemid 19119131)
56. De Marchis F, Ribatti D, Giampietri C, Lentini A, Faraone D, Scoccianti M, et al. Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. Blood 2002; 99: 2045-2053
57. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998; 91: 3289-3299 (Pubitemid 28193879)
58. Spinetti G, Camarda G, Bernardini G, Romano Di Peppe S, Capogrossi MC, Napolitano M. The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. Biochem Biophys Res Commun 2001; 289: 19-24. (Pubitemid 33108785)
59. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-366 (Pubitemid 40563173)
60. Goodman AR, Cardozo T, Abagyan R, Altmeyer A, Wisniewski HG, Vilcek J. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev 1996; 7: 191-202. (Pubitemid 27198077)
61. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994; 15: 81-88 (Pubitemid 24049801)
62. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212.
63. Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep 1996; 23: 253-260 (Pubitemid 27153049)
64. Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol 1995; 7: 54-64.
65. Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003; 24: 148-154 (Pubitemid 36263100)
66. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992; 267: 22190-22197
67. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993; 150: 1804-1812 (Pubitemid 23129656)
68. Kretzschmar D, Hasan G, Sharma S, Heisenberg M, Benzer S. The swiss cheese mutant causes glial hyperwrapping and brain degeneration in Drosophila. J Neurosci 1997; 17: 7425-7432 (Pubitemid 27413273)
69. Lee GW, Goodman AR, Lee TH, Vilcek J. Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins. J Immunol 1994; 153: 3700-3707 (Pubitemid 24313875)
70. Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM. The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum 2008; [Epub ahead of print].
71. Inforzato A, Peri G, Doni A, Garlanda C, Mantovani A, Bastone A, et al. Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. Biochemistry 2006; 45: 11540-11551 (Pubitemid 44454002)
72. Camozzi M, Rusnati M, Bugatti A, Bottazzi B, Mantovani A, Bastone A, et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006; 281: 22605-22613 (Pubitemid 44242289)
73. Berger B, Wilson DB, Wolf E, Tonchev T, Milla M, Kim PS. Predicting coiled coils by use of pairwise residue correlations. Proc Natl Acad Sci USA 1995; 92: 8259-8263
74. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007; 11: 723-738 (Pubitemid 47313297)
75. Inforzato A, Rivieccio V, Morreale AP, Bastone A, Salustri A, Scarchilli L, et al. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J Biol Chem 2008; 283: 10147-10161
76. Introna M, Alles VV, Castellano M, Picardi G, De Gioia L, Bottazzai B, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996; 87: 1862-1872 (Pubitemid 26068902)
77. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272: 32817-32823 (Pubitemid 28023616)
78. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a nonredundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003; 21 (Suppl 2): S43-7. (Pubitemid 36588649)
79. Vouret-Craviari V, Matteucci C, Peri G, Poli G, Introna M, Mantovani A. Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Infect Immun 1997; 65: 1345-1350 (Pubitemid 27146623)
80. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, et al. Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem 1997; 272: 8172-8178 (Pubitemid 27147769)
81. Altmeyer A, Klampfer L, Goodman AR, Vilcek J. Promoter structure and transcriptional activation of the murine TSG-14 gene encoding a tumor necrosis factor/interleukin-1-inducible pentraxin protein. J Biol Chem 1995; 270: 25584-25590
82. Polentarutti N, Bottazzi B, Di Santo E, Blasi E, Agnello D, Ghezzi P, et al. Inducible expression of the long pentraxin PTX3 in the central nervous system. J Neuroimmunol 2000; 106: 87-94. (Pubitemid 30256081)
83. Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 2003; 33: 2886-2893 (Pubitemid 37337154)
84. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F, et al. Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. J Lipid Res 2003; 44: 994-1000. (Pubitemid 37279659)
85. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44: 2841-2850 (Pubitemid 34016204)
86. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22: e10-4.
87. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004; 175: 221-228 (Pubitemid 38942901)
88. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636-641 (Pubitemid 30640663)
89. Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 119: 196-202. (Pubitemid 30064610)
90. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404-1407 (Pubitemid 32641804)
91. Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004; 131: 1577-1586 (Pubitemid 38559284)
92. Milner CM, Day AJ. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci 2003; 116: 1863-1873
93. Milner CM, Higman VA, Day AJ. TSG-6: a pluripotent inflammatory mediator? Biochem Soc Trans 2006; 34: 446-450
94. Maina V, Cotena A, Doni A, Nebuloni M, Pasqualini F, Milner CM, et al. Coregulation in human leukocytes of the long pentraxin PTX3 and TSG-6. J Leukoc Biol 2009.
95. Varani S, Elvin JA, Yan C, DeMayo J, DeMayo FJ, Horton HF, et al. Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. Mol Endocrinol 2002; 16: 1154-1167 (Pubitemid 34621066)
96. Fulop C, Szanto S, Mukhopadhyay D, Bardos T, Kamath RV, Rugg MS, et al. Impaired cumulus mucification and female sterility in tumor necrosis factor-induced protein-6 deficient mice. Development 2003; 130: 2253-2261 (Pubitemid 36656719)
97. Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104: 92-99 (Pubitemid 38879843)
98. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
99. Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 1995; 83: 357-360
100. Richard C, Liuzzo JP, Moscatelli D. Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. J Biol Chem 1995; 270: 24188-24196
101. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, et al. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 2001; 276: 37900-37908 (Pubitemid 37384037)
102. Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Bottazzi B, et al. Pentraxin 3 inhibits fibroblast growth factor 2- dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005; 25: 1837-1842 (Pubitemid 41243451)
103. Liekens S, Neyts J, De Clercq E, Verbeken E, Ribatti D, Presta M. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res 2001; 61: 5057-5064 (Pubitemid 32681535)
104. Nicoli S, Ribatti D, Cotelli F, Presta M. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res 2007; 67: 2927-31.
105. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183
106. Willeke F, Assad A, Findeisen P, Schromm E, Grobholz R, von Gerstenbergk B, et al. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer 2006; 42: 2639-2646 (Pubitemid 44442954)
107. Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008; 7: 3329-3338
108. Ravenna L, Sale P, Di Vito M, Russo A, Salvatori L, Tafani M, et al. Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate 2009; 69(1): 1245-1255
109. Miyamoto T, Leconte I, Swain JL, Fox JC. Autocrine FGF signaling is required for vascular smooth muscle cell survival in vitro. J Cell Physiol 1998; 177: 58-67. (Pubitemid 28421521)
110. Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, et al. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3- derived antiangiogenic pentapeptide. J Cell Mol Med 2009; [Epub ahead of print].
111. Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 2001; 123: 6108-17.
112. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005; 16: 107-137
113. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 2000; 101: 413-424
114. Ragona L, Tomaselli S, Quemener C, Zetta L, Bikfalvi A. New insights into the molecular interaction of the C-terminal sequence of CXCL4 with fibroblast growth factor-2. Biochem Biophys Res Commun 2009; 382: 26-29
115. Wu X, Yan Q, Huang Y, Huang H, Su Z, Xiao J, et al. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med 2008; [Epub ahead of print]..
116. Oyama S, Jr., Miranda MT, Toma IN, Viviani W, Gambarini AG. Mitogenic activity of peptides related to the sequence of human fibroblast growth factor-1. Biochem Mol Biol Int 1996; 39: 1237-1244 (Pubitemid 26306521)
117. Kiyota S, Franzoni L, Nicastro G, Benedetti A, Oyama S, Jr., Viviani W, et al. Introduction of a chemical constraint in a short peptide derived from human acidic fibroblast growth factor elicits mitogenic structural determinants. J Med Chem 2003; 46: 2325-2333 (Pubitemid 36637917)
118. Williams EJ, Williams G, Howell FV, Skaper SD, Walsh FS, Doherty P. Identification of an N-cadherin motif that can interact with the fibroblast growth factor receptor and is required for axonal growth. J Biol Chem 2001; 276: 43879-43886 (Pubitemid 37383955)
119. Facchiano A, Russo K, Facchiano AM, De Marchis F, Facchiano F, Ribatti D, et al. Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. J Biol Chem 2003; 278: 8751-8760 (Pubitemid 36800632)
120. Presta M, Rusnati M, Urbinati C, Sommer A, Ragnotti G. Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): identification of two Asp-Gly-Arg-containing domains involved in the mitogenic activity of bFGF in endothelial cells. J Cell Physiol 1991; 149: 512-524 (Pubitemid 21910220)
121. Terada T, Mizobata M, Kawakami S, Yabe Y, Yamashita F, Hashida M. Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. J Drug Target 2006; 14: 536-545 (Pubitemid 44592887)
122. Ray J, Baird A, Gage FH. A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells. Proc Natl Acad Sci USA 1997; 94: 7047-7052 (Pubitemid 27281988)
123. Schubert D, Ling N, Baird A. Multiple influences of a heparin-binding growth factor on neuronal development. J Cell Biol 1987; 104: 635-643 (Pubitemid 17024718)
124. Baird A, Schubert D, Ling N, Guillemin R. Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc Natl Acad Sci USA 1988; 85: 2324-2328 (Pubitemid 24315884)
125. Walicke PA, Feige JJ, Baird A. Characterization of the neuronal receptor for basic fibroblast growth factor and comparison to receptors on mesenchymal cells. J Biol Chem 1989; 264: 4120-4126 (Pubitemid 19072305)
126. Lin X, Takahashi K, Campion SL, Liu Y, Gustavsen GG, Pena LA, et al. Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo. Int J Mol Med 2006; 17: 833-839
127. Cosic I, Drummond AE, Underwood JR, Hearn MT. In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide. Mol Cell Biochem 1994; 130: 1-9.
128. Kono K, Ueba T, Takahashi JA, Murai N, Hashimoto N, Myoumoto A, et al. In vitro growth suppression of human glioma cells by a 16-mer oligopeptide: a potential new treatment modality for malignant glioma. J Neurooncol 2003; 63: 163-171
129. Ito C, Saitoh Y, Fujita Y, Yamazaki Y, Imamura T, Oka S, et al. Decapeptide with fibroblast growth factor (FGF)-5 partial sequence inhibits hair growth suppressing activity of FGF-5. J Cell Physiol 2003; 197: 272-283 (Pubitemid 37485256)
130. Li S, Christensen C, Kiselyov VV, Kohler LB, Bock E, Berezin V. Fibroblast growth factor-derived peptides: functional agonists of the fibroblast growth factor receptor. J Neurochem 2008; 104: 667-682
131. Tzeng SF, Deibler GE, DeVries GH. Myelin basic protein and myelin basic protein peptides induce the proliferation of Schwann cells via ganglioside GM1 and the FGF receptor. Neurochem Res 1999; 24: 255-260
132. Kiselyov VV, Skladchikova G, Hinsby AM, Jensen PH, Kulahin N, Soroka V, et al. Structural basis for a direct interaction between FGFR1 and NCAM and evidence for a regulatory role of ATP. Structure 2003; 11: 691-701. (Pubitemid 37281184)
133. Berezin V, Bock E. NCAM mimetic peptides: an update. Neurochem Res 2008; [Epub ahead of print].
134. Neiiendam JL, Kohler LB, Christensen C, Li S, Pedersen MV, Ditlevsen DK, et al. An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. J Neurochem 2004; 91: 920-935
135. Hansen SM, Li S, Bock E, Berezin V. Synthetic NCAM-derived Ligands of the Fibroblast Growth Factor Receptor. Neurochem Res 2008.
136. Anderson AA, Kendal CE, Garcia-Maya M, Kenny AV, Morris- Triggs SA, Wu T, et al. A peptide from the first fibronectin domain of NCAM acts as an inverse agonist and stimulates FGF receptor activation, neurite outgrowth and survival. J Neurochem 2005; 95: 570-583 (Pubitemid 41457525)
137. Jacobsen J, Kiselyov V, Bock E, Berezin V. A peptide motif from the second fibronectin module of the neural cell adhesion molecule, NCAM, NLIKQDDGGSPIRHY, is a binding site for the FGF receptor. Neurochem Res 2008; 33(12): 2532-2539
138. Hansen SM, Kohler LB, Li S, Kiselyov V, Christensen C, Owczarek S, et al. NCAM-derived peptides function as agonists for the fibroblast growth factor receptor. J Neurochem 2008; 106: 2030-2041
139. Hagedorn M, Zilberberg L, Lozano RM, Cuevas P, Canron X, Redondo-Horcajo M, et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. Faseb J 2001; 15: 550-552
140. Yayon A, Aviezer D, Safran M, Gross JL, Heldman Y, Cabilly S, et al. Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. Proc Natl Acad Sci USA 1993; 90: 10643-10647 (Pubitemid 23347098)
141. Ballinger MD, Shyamala V, Forrest LD, Deuter-Reinhard M, Doyle LV, Wang JX, et al. Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Nat Biotechnol 1999; 17: 1199-1204
142. Maruta F, Parker AL, Fisher KD, Hallissey MT, Ismail T, Rowlands DC, et al. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther 2002; 9: 543-552 (Pubitemid 34569037)
143. McConnell SJ, Thon VJ, Spinella DG. Isolation of fibroblast growth factor receptor binding sequences using evolved phage display libraries. Comb Chem High Throughput Screen 1999; 2: 155-163
144. Fan H, Duan Y, Zhou H, Li W, Li F, Guo L, et al. Selection of peptide ligands binding to fibroblast growth factor receptor 1. IUBMB Life 2002; 54: 67-72. (Pubitemid 35278621)
145. Kanda S, Shono T, Tomasini-Johansson B, Klint P, Saito Y. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp Cell Res 1999; 252: 262-272 (Pubitemid 29530257)
146. Margosio B, Rusnati M, Bonezzi K, Cordes BL, Annis DS, Urbinati C, et al. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008; 40: 700-709 (Pubitemid 351288589)